Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol EBAG9 contributors: - updated : 01-03-2006
HGNC name estrogen receptor binding site associated, antigen, 9
HGNC id 3123
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
coiled-coil domain necessary for the binding to the receptor
mono polymer homomer , dimer
HOMOLOGY
interspecies homolog to murine Ebag9
Homologene
FAMILY
CATEGORY antigen , protooncogene
SUBCELLULAR LOCALIZATION     intracellular
intracellular,cytoplasm,organelle,membrane
intracellular,cytoplasm,organelle,Golgi
text type III transmembrane protein with a Golgi-predominant localization
basic FUNCTION
  • estrogen-responsive gene inhibiting cell growth
  • may be playing a role in endocrine-immune interactions in breast cancer
  • inducing growth arrest and apoptosis on activated immune cells, mediated by a putative death receptor
  • modulating surface expression of tumor-associated, normally cryptic O-linked glycan structures and contributing indirectly to the antigenicity of tumor cells
  • acting as a ligand for a putative receptor on immune cells such as peripheral lymphocytes and natural killer cells
  • may play important roles in epithelial ovarian cancer
    • CELLULAR PROCESS cell life, cell death/apoptosis
    PHYSIOLOGICAL PROCESS
    text inhibition of cell growth and apoptotic cell death
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein interacting with SNAPAP in the control on large dense-core vesicle zxocyosis
    cell & other
    REGULATION
    induced by estrogens
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in non small cell lung carcinoma with poor prognosis, in squamous cell carcinoma of the oesophagus and in gallbladder cancer and ductal breast cancer in progression with poor prognosis
    tumoral     --over  
    in immune-mediated cholangitis,in primary biliary cirrhosis and in hepatocellular carcinoma with tumour dedifferentiation and increased proliferative activity
    tumoral     --over  
    in uterine endometrial cancer
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    ANIMAL & CELL MODELS